| COMPANY | SYMBOL | TYPE | PRICE | Shares | Trade Date | UNDERWRITER (S) |
| Achaogen, Inc. | AKAO | IPO | $12.00-$14.00 | 6 million | 3/12/2014 | Credit Suisse, Cowen & Co. |
| AdaptImmune Therapeutics | ADAP | IPO | $15.00-$17.00 | 11.25 million | 5/6/2015 | BofA Merrill Lynch, Cowen & Co., Leerink Partners
|
| Akcea Therapeutics, Inc. | AKCA | IPO | $12.00-$14.00 | 15.63 million | 7/14/2017 | Cowen and Company, Stifel, Wells Fargo Securities |
| Allena Pharmaceuticals, Inc. | ALNA | IPO | $14.00-$16.00 | 5.3 million | 11/2/2017 | Credit Suisse, Jefferies, Cowen & Company |
| Aquinox Pharmaceuticals, Inc. | AQXP | IPO | $10.00-$12.00 | 4.2 million | 3/7/2014 | Jefferies, Cowen & Co. |
| Argenx N.V. | ARGX | IPO | Last Trade $18.18 | 5.0 million ADS | 5/18/2017 | Cowen and Company, Piper Jaffray |
| Asante Solutions, Inc. | PUMP | IPO | $13.00-$15.00 | 3.5 million | 0/0/0 | Leerink Partners, Cowen and Company
|
| Audentes Therapeutics, Inc. | BOLD | IPO | $14.00-$16.00 | 5 million | 7/20/2016 | BofA Merrill Lynch, Cowen & Co., Piper Jaffray |
| Avalanche Biotechnologies, Inc. | AAVL | IPO | $13.00-$15.00 | 5.4 million | 7/31/2014 | Jefferies, Cowen & Co., Piper Jaffray |
| Avinger, Inc. | AVGR | IPO | $12.00-$14.00 | 5 million | 1/30/2015 | Canaccord Genuity, Cowen & Co.
|
| BeiGene, Ltd. | BGNE | IPO | $15.00-$17.00 | 6.6 million | 2/3/2016 | Goldman Sachs & Co., Morgan Stanley, Cowen & Co. |
| Bellerophon Therapeutics | BLPH | IPO | $14.00-$16.00 | 4 million | 2/13/2015 | Leerink Partners, Cowen & Co. |
| Bind Therapeutics, Inc. | BIND | IPO | $14.00-$16.00 | 4.7 million | 9/20/2013 | Credit Suisse, Cowen & Co. |
| Blueprint Medicines Corporation | BPMC | IPO | $15.00-$17.00 | 8.15 million | 4/30/2015 | Goldman Sachs & Co., Cowen & Co. |
| Catabasis Pharmaceuticals | CATB | IPO | $13.00-$15.00 | 5 million | 6/25/2015 | Citigroup, Cowen & Co. |
| Cempra Holdings | CEMP | IPO | $11.00-$13.00 | 6 million | 2/3/2012 | Stifel Nicolaus Weisel, Leerink Swann, Cowen and Company |
| Chiasma, Inc. | CHMA | IPO | $13.00-$15.00 | 6.36 million | 7/16/2015 | Barclays, Cowen & Co. |
| Clearside Biomedical | CLSD | IPO | $7.00-$7.00 | 7.2 million | 6/2/2016 | Cowen & Co., Stifel |
| Corvus Pharmaceuticals | CRVS | IPO | $15.00-$17.00 | 4.7 million | 3/23/2016 | Credit Suisse, Cowen & Co., Guggenheim Securities |
| CytomX Therapeutics | CTMX | IPO | $14.00-$16.00 | 6.7 million | 10/8/2015 | BofA Merrill Lynch, Jefferies, Cowen & Co. |
| Eleven Biotherapeutics | EBIO | IPO | $13.00-$15.00 | 5 million | 2/6/2014 | Citigroup, Cowen & Co., Leerink Swann |
| EVO Payments, Inc. | EVOP | IPO | $14.00-$16.00 | 14 million | 5/23/2018 | J.P. Morgan, BofA Merrill Lynch, Citigroup, Deutsche Bank Securities, SunTrust Robinson Humphrey, Barclays, Cowen and Company, Goldman Sachs & Co., Regions Securities LLC, William Blair |
| Fate Therapeutics, Inc. | FATE | IPO | $6.00-$8.00 | 6.7 million | 10/1/2013 | Cowen & Co., BMO Capital Markets |
| Foamix Pharmaceuticals | FOMX | IPO | $10.00-$12.00 | 6.7 million | 9/18/2014 | Barclays, Cowen and Company
|
| Foghorn Therapeutics Inc. | FHTX | IPO | $15.00-$17.00 | 7.5 million | 10/23/2020 | Goldman Sachs, Morgan Stanley, Cowen |
| G1 Therapeutics, Inc. | GTHX | IPO | $15.00-$17.00 | 7 million | 5/17/2017 | J.P. Morgan, Cowen and Company |
| GC Aesthetics plc | GCAA | IPO | $13.00-$15.00 | Withdrawn | 0/0/0 | BofA Merrill Lynch, Deutsche Bank Securities, Cowen and Company |
| Histogenics Corporation | HSGX | IPO | $13.00-$15.00 | 5.91 million | 12/3/2014 | Cowen & Co., Needham & Co., Canaccord Genuity |
| Hyperion Therapeutics, Inc | HPTX | IPO | $11.00-$13.00 | 5 million | 7/26/2012 | Leerink, Cowen & Company |
| Inotek Pharmaceuticals Corporation | ITEK | IPO | $13.00-$15.00 | 6.67 million | 2/18/2015 | Cowen & Co., Piper Jaffray
|
| Jounce Therapeutics | JNCE | IPO | $13.00-$15.00 | 6.365 million | 1/27/2017 | J.P. Morgan, Cowen and Company |
| KemPharm, Inc. | KMPH | IPO | $12.00-$14.00 | 5.09 million | 4/16/2015 | Cowen & Co., RBC Capital Markets |
| Kite Pharma, Inc., | KITE | IPO | $15.00-$16.00 | 7.5 million | 6/20/2014 | Jefferies, Credit Suisse, Cowen and Co. |
| Loxo Oncology, Inc. | LOXO | IPO | $12.00-$14.00 | 5.3 million | 8/1/2014 | Cowen & Co., Stifel |
| Luxoft Holding | LXFT | IPO | $16.00-$18.00 | 4.1 million | 6/26/2013 | UBS Investment Bank, Credit Suisse, J.P. Morgan, VTB Capital, Cowen & Co.
|
| Mersana Therapeutics, Inc. | MRSN | IPO | $14.00-$16.00 | 5 million | 6/28/2017 | J.P. Morgan, Cowen and Company, Leerink Partners |
| MyoKardia, Inc. | MYOK | IPO | $15.00-$17.00 | 5.4 million | 10/29/2015 | Credit Suisse, Cowen & Co. |
| Myovant Sciences, Ltd. | MYOV | IPO | $12.00-$15.00 | 14.5 million | 10/27/2016 | Citigroup, Cowen and Company, Evercore ISI, Barclays |
| Nant Health | NH | IPO | $12.50-$15.50 | 6.5 million | 6/2/2016 | Jefferies, Cowen & Co. |
| Natera, Inc. | NTRA | IPO | $15.00-$17.00 | 10 million | 7/2/2015 | Morgan Stanley, Cowen & Co., Piper Jaffray |
| Neuroderm, Ltd. | NDRM | IPO | $13.00-$16.00 | 4.5 million | 11/14/2014 | Jefferies, Cowen & Co. |
| Newsummit Biopharma Holdings | NSB | IPO | TBD | TBD | 0/0/0 | Oppenheimer & Co., Cowen & Co. |
| Nexvet Biopharma plc | NVET | IPO | $13.00-$16.00 | 4 million | 2/5/2015 | BofA Merrill Lynch, Cowen & Co. |
| Nivalis Therapeutics | NVLS | IPO | $13.00-$15.00 | 5.5 million | 6/17/2015 | Cowen & Co., Stifel |
| Ocular Therapeutix | OCUL | IPO | $14.00-$16.00 | 5 million | 7/25/2014 | Morgan Stanley, Cowen & Co., RBC Capital Markets |
| Ovid Therapeutics Inc. | OVID | IPO | $15.00-$17.00 | 5 million | 5/5/2017 | Citigroup, Cowen and Company |
| Quotient Limited | QTNTU | IPO | $14.00-$16.00 | 5 million | 4/25/2014 | UBS Investment Bank, Baird, Cowen & Co. |
| Radius Health | RDUS | IPO | $8.00-$8.00 | 6.5 million | 6/6/2014 | Jefferies, Cowen & Co. |
| Raindance Technologies | RAIN | IPO | TBD | TBD | 0/0/0 | BofA Merrill Lynch, Cowen and Company, Evercore ISI |
| Reata Pharmaceuticals | RETA | IPO | $14.00-$16.00 | 5.5 million | 5/26/2016 | Citigroup, Cowen & Co., Piper Jaffray |
| Regulus Therapeutics Inc. | RGLS | IPO | $10.00-$12.00 | 11.25 million | 9/7/2012 | Lazard Capital Markets, Cowen and Company, BMO Capital Markets
|
| Revance Therapeutics, Inc. | RVNC | IPO | $14.00-$16.00 | 6 million | 2/6/2014 | Cowen & Co., Piper Jaffray |
| Rhythm Pharmaceuticals, Inc. | RYTM | IPO | $14.00-$16.00 | 7.05 million | 10/5/2017 | Morgan Stanley, BofA Merrill Lynch, Cowen & Co. |
| Sinocom Pharmaceutical, Inc. | TBD | IPO | TBD | TBD | 0/0/0 | Cowen & Co., Macquarie Capital |
| Spero Therapeutics, Inc. | SPRO | IPO | $14.00-$16.00 | 5.5 million | 11/2/2017 | BofA Merrill Lynch, Cowen & Company, Stifel |
| Syros Pharmaceuticals | SYRS | IPO | $14.00-$16.00 | 4 million | 6/30/2016 | Cowen & Co., Piper Jaffray |
| Turning Point Brands | TPB | IPO | $13.00-$15.00 | 5.4 million | 5/11/2016 | Cowen & Co., FBR |
| UroGen Pharma Ltd. | URGN | IPO | $12.00-$14.00 | 4.47 milliion | 5/4/2017 | Jefferies, Cowen and Company |
| ViewRay Incorporated | VRAY | IPO | $12.00-$14.00 | 4 million | 0/0/0 | Cowen and Company, Stifel |
| Viventia Bio, Inc. | VITA | IPO | TBD | TBD | 0/0/0 | Leerink Securites, Cowen and Company, Guggenheim Securities |
| Voyager Therapeutics | VYGR | IPO | $15.00-$17.00 | 5 million | 11/11/2015 | Cowen & Co., Piper Jaffray, Nomura, Wedbush PacGrow |
| Xtera Communications | XCOM | IPO | $9.00-$11.00 | 5 million | 11/12/2015 | Needham & Co., Cowen & Co., BMO Capital Market |
| Zafgen, Inc. | ZFGN | IPO | $14.00-$16.00 | 6 million | 6/19/2014 | Leerink Partners, Cowen and Company
|
© 2005 - 2024 IPO Boutique. All Rights Reserved